2644-70-4 Usage
Chemical Properties
Hydrazine monohydrochloride is white to slightly beige crystals or cryst. powder; melts at 93°C; decomposes around 200°C; very soluble in water (37 g/100mL at 20°C); slightly soluble in alcohol.
Physical properties
White flakes; orthorhombic crystals; density 1.5 g/cm3; melts at 93°C;decomposes around 200°C; very soluble in water (37 g/100mL at 20°C); slightly soluble in alcohol.
Uses
Different sources of media describe the Uses of 2644-70-4 differently. You can refer to the following data:
1. Hydrazine monohydrochloride has been used:as catalyst in the synthesis of titanium oxide polymers via catalytic sol-gel processin fabrication of amorphous titanium dioxide (TiO2) thin films exhibiting high refractive indices and high transparencyin preparation of ethyl 3-ethoxy-1H-pyrazole-4-carboxylate
2. Hydrazine hydrochloride is used to prepare other hydrazine derivatives.
Preparation
Hydrazine hydrochloride is prepared by the reaction of hydrazine with hydrogen chloride:
N2H4 + HCl → N2H4 ?HCl
Hazard
Hydrazine hydrochloride is moderately toxic by all routes of exposure. Theoral LD50in mice is 126 mg/kg.
Purification Methods
Prepare it by dropwise addition of cold conc HCl to cold liquid hydrazine in equimolar amounts. The crystals are harvested from water and are twice recrystallised from absolute MeOH and dried under a vacuum. [Kovack et al. J Am Chem Soc 107 7360 1985.]
Toxicity evaluation
Hydrazine hydrochloride is moderately toxic by all routes of exposure. The oral LD50 in mice is 126 mg/kg.
Check Digit Verification of cas no
The CAS Registry Mumber 2644-70-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,6,4 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2644-70:
(6*2)+(5*6)+(4*4)+(3*4)+(2*7)+(1*0)=84
84 % 10 = 4
So 2644-70-4 is a valid CAS Registry Number.
InChI:InChI=1/ClH.H4N2/c;1-2/h1H;1-2H2/p-1
2644-70-4Relevant articles and documents
Methods of treating cytokine mediated diseases
-
, (2008/06/13)
Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.
Process for producing cyclic hydrazine derivatives, tetra-hydropyridazine and hexahydropyridazine
-
, (2008/06/13)
The present invention relates to a process for producing alicyclic hydrazine derivatives, tetrahydropyridazine and hexahydropyridazine which are useful as intermediate starting materials such as medicines and agricultural chemicals. Especially, the present invention provides; a process for producing an alicyclic hydrazine derivative or its hydrohalogenic acid salt, which comprises reacting a hydrazine hydrohalogenic acid salt with a diol compound or an alicyclic ether compound in the presence of an excessive inorganic acid existing in a free form or in the form of an acid addition salt; a process for producing tetrahydropyridazine from 1-aminopyrrolidine, which comprises oxidizing 1-aminopyrrolidine with an oxidizing agent to form tetrahydropyridazine; and a process for producing hexahydropyridazine, which comprises oxidizing 1-aminopyrrolidine with an oxidizing agent, synthesizing tetrahydropyridazine, and thereafter, hydrogenating the tetrahydropyridazine in the presence of a base.
